Article

Regorafenib in Bone Sarcoma: A Systematic Review and Meta-Analysis of Its Effectiveness and Safety in Cancer Treatment

2025-08-06

Abstract excerpt

<h4>Objectives</h4> Bone sarcomas are aggressive malignancies with limited treatment options in advanced stages. Regorafenib, an oral multi-kinase inhibitor, has showed potential efficacy in early-phase trials. However, its overall effectiveness and safety profile in bone sarcoma remain unclear. This systematic review and meta-analysis aim to assess the clinical impact of regorafenib on survival outcomes and adve...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a3af9274-ce13-54b1-a2b9-15f5584338ba
DOI: 10.1101/2025.08.04.25332569

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Regorafenib in Bone Sarcoma: A Systematic Review and Meta-Analysis of Its Effectiveness and Safety in Cancer TreatmentDOI 10.1101/2025.08.04.25332569Read

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanibSemantic proximity Read

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Semantic proximity Read

Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and ChemoresistanceSemantic proximity Read

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task ForceSemantic proximity Read

Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.Semantic proximity Read

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read

Targeted treatment of soft-tissue sarcomaSemantic proximity Read

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)Semantic proximity Read

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.Semantic proximity Read

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.Semantic proximity Read